A paper published in the current issue of P&P by a group of researchers of the University of Bologna (headed by Professor Giovanni Fava) and a Harvard psychopharmacologist (professor Ross Baldessarini) has analyzed data that derive from randomized controlled trials concerned with the use of antidepressant drugs in children and adolescents. The results are shocking: in at least one patient out of 10 antidepressants cause mood elevation and behavioral activation that may persist long after drug administration and create a permanent state of mood instability.
Authors compared reports of antidepressant trials (n =6,767 subjects) in juvenile depressive (n = 17) and anxiety disorders (n = 25) for consensus-based indications of psychopathological mood elevation or behavioral activation. Rates of excessive arousal-activation during treatment with antidepressants were at least as high in juvenile anxiety (13.8%) as depressive (9.79%) disorders, and much lower with placebos. Risks of excessive mood elevation during antidepressant treatment, including mania-hypomania, were much greater than with placebo, and similar in juvenile anxiety and depressive disorders. Excessive arousal-activation in children or adolescents treated with antidepressants for anxiety as well as depressive disorders calls for particular caution and monitoring for potential risk of future bipolar disorder.
Experts recommend cascade screening over universal lipid screening for familial hypercholesterolemia